Creative Med Technology Hldgs Stock Price, News & Analysis

Creative Medical Technology Holdings (NASDAQ: CELZ) announced regulatory approval on January 6, 2026 for its BioDefense Inc. Burn Pit Initiative, allowing the program to proceed nationally to collect expanded molecular and cellular data from veterans affected by burn pit exposure.

The company said no additional fundraising is required; the program will be funded using existing partnerships (including Greenstone Biosciences), internal infrastructure, and prior vendor relationships to support AI-driven molecular modeling, iPSC development, and regenerative countermeasure work.

Creative Medical Technology (NASDAQ: CELZ) announced on Dec 17, 2025 that it has completed patient enrollment in the FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel) for chronic lower back pain associated with degenerative disc disease. A prior independent DSMB safety review confirmed a favorable safety profile with no significant adverse events. With enrollment finished, the program moves to follow-up and data analysis as the company advances toward topline safety and efficacy readouts and late-stage development planning.

Creative Medical (NASDAQ: CELZ) announced on Dec 2, 2025 that the World Health Organization approved olastrocel as the International Non‑Proprietary Name (INN) for the active cellular substance in its lead allogeneic cell therapy CELZ‑201 (AlloStem).

The INN gives a globally standardized scientific name to the asset, aiding regulatory and clinical clarity, pharmacovigilance, labeling, and international development. Company leadership said the milestone supports global advancement and complements the program’s FDA Fast Track designation in degenerative disc disease. Olastrocel is being developed as an off‑the‑shelf perinatal‑tissue cell therapy for chronic lower back pain/DDD, new‑onset type 1 diabetes, and biodefense‑related indications.

Creative Medical Technology Holdings (NASDAQ: CELZ) launched the BioDefense Inc. Veterans Initiative on Oct 30, 2025 to address long-term health effects from U.S. burn pit exposure using its proprietary iPSC regenerative platform and AI analytics.

The program will build a national-scale molecular database of toxic-exposure signatures, develop iPSC-based regenerative repair models, and deploy AI/ML exposure-classification and predictive-disease models. Greenstone Biosciences was named exclusive AI and iPSC development partner to provide sequencing, proteomics, and machine-learning support.

Creative Medical Technology Holdings (NASDAQ: CELZ) entered agreements for immediate exercise of warrants to purchase 1,116,136 shares at an exercise price of $3.75 per share, generating approximately $4.2 million gross proceeds before advisory fees. The shares issuable upon exercise are registered on Form S-3.

In consideration, the company will issue new unregistered warrants exercisable for up to 2,790,340 shares at $3.75, subject to a post-issuance five-day VWAP reduction; new warrants will be exercisable for five years following shareholder approval. The company also agreed to reduce exercise prices on certain May 2022 warrants to $4.73. Transaction expected to close on or about October 29, 2025. Net proceeds intended for working capital and general corporate purposes.

Creative Medical Technology Holdings (NASDAQ: CELZ) issued a shareholder letter outlining clinical, IP, and AI milestones that frame near-term catalysts for 2026. The company is advancing two FDA-cleared programs: CELZ-201-DDT (ADAPT) for degenerative disc disease with FDA Fast Track and topline results expected in H1 2026, and CELZ-201 (CREATE-1) for new-onset Type 1 Diabetes with early data expected in 2026. The firm reports > 6 billion cGMP clinical-grade AlloStem cells manufactured, an IP portfolio of > 60 patents/pending, and two U.S. patents issued in Q3 2025 (Type 1 Diabetes exp. 2043; Heart Failure exp. 2042). The company highlights AI integration for iPScelz and emphasizes capital discipline while targeting scalable commercialization paths.

Creative Medical (NASDAQ: CELZ) announced receipt of two U.S. patents for its ImmCelz™ regulatory T cell platform and congratulated the 2025 Nobel laureates for Treg discoveries. The company named U.S. Patent 12931925B2 (expires 2043-05-24) for prevention/treatment of Type 1 diabetes via myeloid suppressor cell augmentation, and U.S. Patent 12385011B2 (expires 2042-12-15) for treating heart failure and post-infarct remodeling using ex vivo reprogrammed immune cells. Creative Medical said ImmCelz™ uses "supercharged" regulatory T cells, is being evaluated in the ongoing CREATE-1 clinical trial, and targets a U.S. treatable heart failure population of over 5 million and >b>6 million refractory angina candidates.

The release positions these patents as IP protection through 2042–2043 and highlights the company’s aim to translate Treg biology into regenerative immunotherapies.

Creative Medical Technology Holdings (NASDAQ: CELZ) has received FDA Fast Track designation for CELZ-201-DDT, its lead therapy targeting degenerative disc disease (DDD) and chronic lower back pain. The designation enables accelerated FDA interactions, rolling BLA submissions, and priority review eligibility.

CELZ-201-DDT, part of the AlloStem® platform, is an allogeneic perinatal cell therapy administered through minimally invasive intramuscular injections. The therapy has shown promising safety data and early efficacy signs in clinical trials. The global spinal disorders treatment market is projected to exceed $20 billion by 2030.

Creative Medical Technology (NASDAQ: CELZ) has received a Notice of Allowance from the USPTO for a patent application focused on treating Type 1 Diabetes using cell-based immunotherapy. The patent, effective until at least 2040, covers the use of the Company's ImmCelzTM product, which utilizes supercharged T regulatory cells with proprietary cell-free solutions.

The technology has been validated using cells from Type 1 Diabetes patients and aims to address the autoimmune condition where the body attacks insulin-producing beta cells. The patent allowance aligns with the Company's ongoing CREATE-1 clinical trial and strengthens their intellectual property portfolio in regenerative medicine.